Interpretation:

Among patients with prediabetes, liraglutide appeared to be beneficial at preventing the development of type 2 diabetes. Liraglutide compared with placebo was also associated with greater reduction in bodyweight and glycated hemoglobin. A limitation of the trial is that a large proportion of individuals in both treatment arms withdrew from follow-up.